{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-006664","form_type":"8-K","ticker":"GLSI","cik":"0001799788","company_name":"Greenwich LifeSciences, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.573121+00:00","generated_at":"2026-06-06T02:32:44.541471+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Greenwich LifeSciences expands Phase III Flamingo-01 arm to 250 patients; European sites pending","bullets":["DSMB recommended continue as is; no serious adverse events related to GLSI-100 reported to date.","Non-HLA-A*02 open-label arm expanded from 100 to 250 patients per Steering Committee guidance.","European regulatory approval expected 2024; contracts for 105-120 sites in Spain, France, Germany, Italy, Poland.","First 3 commercial lots of GP2 completed in 2023; enough for ~200,000 doses; commercial vial filling planned 2024.","Phase II data review found potential recurrence in treated arm (Q4 2023); company states no material effect on study power."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-006664","json":"https://secwatch.observer/filing/0001493152-24-006664.json","markdown":"https://secwatch.observer/filing/0001493152-24-006664.md","text":"https://secwatch.observer/filing/0001493152-24-006664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799788/000149315224006664/0001493152-24-006664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799788/000149315224006664/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:32:44.541471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}